Department of Hematology, Southern Medical University, Zhujiang Hospital, 253# industry road, Guangzhou, Guangdong, 510282, China.
Department of Radiotherapy, Southern Medical University, Zhujiang Hospital, 253# industry road, Guangzhou, Guangdong, 510282, China.
J Exp Clin Cancer Res. 2018 Jan 31;37(1):18. doi: 10.1186/s13046-017-0639-5.
Radioresistance is a major challenge during the treatment of NK/T cell lymphoma. This study aimed to investigate the potential role of MicroRNA-150 (miR-150) in increase the sensitivities of NK/T cell lymphoma to ionizing radiation.
In this study, we found that miR-150 was significantly decreased in NK/T cell lymphoma tissues and cell lines. Low expression of miR-150 was positively associated with therapeutic resistance in 36 NK/T cell lymphoma cases. Our further in vitro and in vivo studies illustrated that overexpression of miR-150 substantially enhanced the sensitivity of NK/T cell lymphoma cells to ionizing radiation treatment. Furthermore, luciferase reporter assays in NK/T cell lymphoma cells transfected with the AKT2 or AKT3 three prime untranslated region reporter constructs established AKT2 and AKT3 as direct targets of miR-150. The phosphatidylinositol 3-kinase inhibitor LY294002 was used to inhibit Akt to verify miR-150 increase NK/T cell lymphoma cell radiorsensitivity through suppress the PI3K/AKT/mTOR pathway.
Taken together, this study demonstrates that miR-150 might serve as a potential therapeutic sensitizer through inhibition of the AKT pathway in NK/T cell lymphoma treatment.
耐放射是 NK/T 细胞淋巴瘤治疗中的一个主要挑战。本研究旨在探讨 MicroRNA-150(miR-150)在增加 NK/T 细胞淋巴瘤对电离辐射敏感性方面的潜在作用。
在这项研究中,我们发现 miR-150 在 NK/T 细胞淋巴瘤组织和细胞系中显著下调。36 例 NK/T 细胞淋巴瘤病例中,miR-150 低表达与治疗耐药性呈正相关。我们进一步的体外和体内研究表明,miR-150 的过表达显著增强了 NK/T 细胞淋巴瘤细胞对电离辐射治疗的敏感性。此外,在转染 AKT2 或 AKT3 3′非翻译区报告构建体的 NK/T 细胞淋巴瘤细胞中进行的荧光素酶报告基因测定表明,AKT2 和 AKT3 是 miR-150 的直接靶标。使用磷脂酰肌醇 3-激酶抑制剂 LY294002 抑制 Akt 以验证 miR-150 通过抑制 PI3K/AKT/mTOR 通路增加 NK/T 细胞淋巴瘤细胞放射敏感性。
综上所述,本研究表明,miR-150 可能通过抑制 AKT 通路成为 NK/T 细胞淋巴瘤治疗中的一种潜在治疗增敏剂。